How Specific Are Antibody Drugs?
Are conventional specificity tools missing critical off-target interactions?
Recent findings suggest that up to one-third of antibody drugs display off-target binding, raising concerns about drug attrition and patient safety. Could better tools improve approvals and mitigate risks?
𝗝𝗼𝗶𝗻 𝘂𝘀 𝗳𝗼𝗿 𝗮 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝘄𝗶𝘁𝗵 𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝗹 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿, exploring how cell-based protein arrays are emerging as a powerful alternative for evaluating antibody specificity.
Diana Norden & Kris Raghavan, Ph.D. 𝘄𝗶𝗹𝗹 𝗱𝗶𝘀𝗰𝘂𝘀𝘀:
– How 𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝗹 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿’𝘀 𝗠𝗲𝗺𝗯𝗿𝗮𝗻𝗲 𝗣𝗿𝗼𝘁𝗲𝗼𝗺𝗲 𝗔𝗿𝗿𝗮𝘆𝗧𝗠 (𝗠𝗣𝗔) detects off-target interactions missed in traditional studies
– Why early detection of polyspecificity can help 𝗿𝗲𝗱𝘂𝗰𝗲 𝗱𝗿𝘂𝗴 𝘁𝗼𝘅𝗶𝗰𝗶𝘁𝘆 𝗮𝗻𝗱 𝗮𝘁𝘁𝗿𝗶𝘁𝗶𝗼𝗻
– What this means for 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 moving forward